Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07441486
PHASE2
A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer
Sponsor: Tianjin Medical University Cancer Institute and Hospital
View on ClinicalTrials.gov
Summary
Objective: To explore the curative effect and safty of Changchun Ruibin metronomic chemotherapy combined with endistat in the treatment of HR positive HER2 negative advanced breast carcinoma.
Key Details
Gender
FEMALE
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-04-01
Completion Date
2026-08-30
Last Updated
2026-03-02
Healthy Volunteers
No
Conditions
Interventions
DRUG
Entinostat
Entinostat will be administered according to the study protocol.
DRUG
Oral Paclitaxel
Oral paclitaxel will be administered according to the study protocol.